EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Enhancement of Statin Effects on Lipid Lowering and Reduction of Cardiovascular Risk Score by (−)‐Epicatechin in Proof‐of‐Concept Pilot Study

Cameron K Ormiston iD, Aryana Pazargadi, Ashley Rosander, Guillermo Ceballos iD, Francisco Villarreal iD, Pam R Taub iD

Clinical and Translational Science · 2025

DOI: 10.1111/cts.70236 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Cameron K Ormiston und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Medicine, Department of Medicine, University of California, San Diego, La Jolla, California, USA. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Catechin, Atherosclerosis, Cardiovascular Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: BLRD VA, NIH HHS, AHA Scientist Development Grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Statins play an instrumental role in reducing and managing atherosclerotic cardiovascular disease (ASCVD) but can be difficult to tolerate due to muscle‐associated side effects. There remains an unmet need for strategies that improve statin tolerance and synergize their effect on atherogenic lipids. (−)‐Epicatechin (Epi) is a natural flavonoid that can improve lipid biomarkers and mitochondrial function. This study explored the capacity of Epi to augment statin's beneficial effects on lipid profile and ASCVD risk parameters. In total, 19 patients completed a randomized, double‐blind placebo‐controlled trial. The study consisted of two cohorts. Cohort 1 consisted of healthy patients with elevated low‐density lipoprotein (LDL) > 100 mg/dL and was used to determine appropriate Epi dosing. Cohort 2 consisted of patients with metabolic syndrome. Patients were randomized into statin‐only ( n = 8; 5 in Cohort 2) or statin + Epi ( n = 11; 8 in Cohort 2) for 3 months. VO 2 max and lipid biomarkers were assessed at baseline and at the end of 3 months. Final analysis included Cohort 2 only. The statin + Epi group saw significant beneficial changes in total cholesterol ( p = 0.002) and non‐HDL cholesterol ( p = 0.007). There was a significantly larger increase in HDL ( p = 0.037) and significantly greater decrease in LDL particle number ( p = 0.0003) and small LDL particle number ( p = 0.003) among the statin + Epi group compared to statin‐only. Ten‐year ASCVD risk was significantly lower at end‐of‐study for the statin + Epi arm compared to statin‐only ( p < 0.05). No VO 2 max differences were found. This is the first proof‐of‐concept study to show combination therapy of a statin with Epi is safe and effective in augmenting statin‐associated improvements in lipid biomarkers. Trial Registration: ClinicalTrials.gov : NCT02490527

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hydroxymethylglutaryl-CoA Reductase InhibitorsCatechinAtherosclerosisCardiovascular DiseasesHumansMaleFemalePilot ProjectsMiddle AgedDouble-Blind MethodAgedProof of Concept StudyTreatment OutcomeBiomarkersDrug Therapy, CombinationHeart Disease Risk FactorsMetabolic SyndromeLipids

Stichwörter der Autor:innen

epicatechinflavonoidslipid profilemetabolic syndromestatin

Substanzen

Hydroxymethylglutaryl-CoA Reductase InhibitorsCatechinBiomarkersLipids

Autor:innen und Institutionen

  • Division of Cardiovascular Medicine, Department of Medicine, University of California, San Diego, La Jolla, California, USA.
  • Department of Medical Education, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Rocky Vista University, Ivins, Utah, USA.
  • Sección de Estudios de Posgrado, Escuela Superior de Medicina, Instituto Politécnico Nacional, Mexico City, México.
  • School of Medicine, University of California San Diego, San Diego, California, USA.

ORCID-Profile: Cameron K Ormiston, Guillermo Ceballos, Francisco Villarreal, Pam R Taub

Förderung

  • BLRD VA
  • NIH HHS
  • AHA Scientist Development Grant
  • National Institutes of Health

Zitieren

APA

Ormiston, C. K., Pazargadi, A., Rosander, A., Ceballos, G., Villarreal, F., & Taub, P. R. (2025). Enhancement of Statin Effects on Lipid Lowering and Reduction of Cardiovascular Risk Score by (−)‐Epicatechin in Proof‐of‐Concept Pilot Study. Clinical and Translational Science. https://doi.org/10.1111/cts.70236

Vancouver

Ormiston CK, Pazargadi A, Rosander A, Ceballos G, Villarreal F, Taub PR. Enhancement of Statin Effects on Lipid Lowering and Reduction of Cardiovascular Risk Score by (−)‐Epicatechin in Proof‐of‐Concept Pilot Study. Clinical and Translational Science. 2025. doi:10.1111/cts.70236

BibTeX
@article{Ormiston2025,
  author = {Ormiston, Cameron K and Pazargadi, Aryana and Rosander, Ashley and Ceballos, Guillermo and Villarreal, Francisco and Taub, Pam R},
  title = {Enhancement of Statin Effects on Lipid Lowering and Reduction of Cardiovascular Risk Score by (−)‐Epicatechin in Proof‐of‐Concept Pilot Study},
  journal = {Clinical and Translational Science},
  year = {2025},
  doi = {10.1111/cts.70236}
}
Kostenlos starten →